MELBOURNE, Australia, April 08, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce an innovative partnership between GTG, and Humanise Health launching a "Know Your Risk" event featuring the company's unique Risk Assessment portfolio, to be held at The Langham, Pasadena, California on the 21st of May. This unique gathering is dedicated to empowering women by ...

MELBOURNE, Australia, April 02, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to report the company's new digital strategy, led by the company's recently appointed strategic advisor, Dr. Malcolm Bohm, is having a significant positive impact across all facets of GTG's social media platforms. The various analytical markers all showed uplifts, in some cases there was ...

MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, "Company", "GTG"))), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company's geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up throughout the remainder of the year. The U.S. wellness testing market is projected ...

Commission file number 000-51504 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EX- CHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SEC ...

Exhibit 99.1 Highlighting our commercial progress, the company announces revenues for the 12 months ending June 30, 2023, of A$8.686million, an increase of +A$1.891m; +28% compared with 2022. Momentum building - Growth and Partnerships: The dedication of our team, and the power of geneType, have ignited a revolution in healthcare. We are seeing encouraging growth in our commercial volumes for geneType, a testament to the value and trust we are building in the medical community. Twenty medical practices in b ...

Company Participants Simon Morriss - Chief Executive Officer Carl Stubbings - Chief Commercial Officer Thank you for joining us, and afternoon for those joining us from the U.S. IÂ'm really pleased to have both Simon Morriss, the Chief Executive Officer of Genetic Technologies; and Tony Di Pietro, the CFO of Genetic as well. Simon Morriss Some of the key messages that I really want to help take, deliver and you to take out of today's call. We, as a team, with a Board and an Executive, have developed a clear ...

Genetic Technologies Limited (NASDAQ:GENE) Q3 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Adrian Mulcahy - Investor Relations Tony Di Pietro - Chief Financial Officer Conference Call Participants [Abrupt Start] FY 2023. I'm really pleased to have both Simon Morriss, the CEO; and Tony Di Pietro. Some of you may not have met before, who is the CFO for Genetic Technologies. So, without any further ado, let me pass over to you, Simon to get us underway. Simon Morriss And as Adrian mentioned at the star ...

Adrian Mulcahy - Investor Relations Carl Stubbings - Chief Commercial Officer Â…for those in the US that are joining us this morning and this afternoon for Genetic Technologies First Half FY '23 Investor Webinar. With us today are Simon Morriss, CEO, Tony Di Pietro, the CFO and Carl Stubbings, the Chief Commercial Officer. Simon Morriss We operate three brands across the world. Our GeneType brands to serious disease, EasyDNA and AffinityDNA for a more consumer-based genomic test across Europe, America and S ...

Genetic Technologies Limited (NASDAQ:GENE) Q1 2023 Earnings Conference Call November 3, 2022 8:00 PM ET Company Participants Adrian Mulcahy - Investor Relations Simon Morriss - Chief Executive Officer Adrian Mulcahy [Starts Abruptly] Genetic Technologies First Quarter FY '23 Investor Webinar. We have with us today, which is great news, is Simon Morriss, the CEO of Genetic Technologies. And the way we're going to run this is, Simon is going to go through some prepared slides, he's going to talk through some ...

Genetic Technologies Limited (NASDAQ:GENE) Q3 2022 Earnings Conference Call April 20, 2022 6:00 PM ET Company Participants Simon Morriss – Chief Executive Officer Mike Tonroe – Chief Financial Officer Dr. George Muchnik – Non-Executive Director and Medical Advisor Conference Call Participants MichaelTonroe Hello and welcome to our Quarter Three business update. I'm Mike Tonroe, Chief Financial Officer Genetic Technologies. I'm also your house and moderator. Thank you for taking the time to join us today. Th ...